DK0744958T3
(da)
|
1994-01-31 |
2003-10-20 |
Univ Boston |
Polyklonale antistofbiblioteker
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
US6759243B2
(en)
|
1998-01-20 |
2004-07-06 |
Board Of Trustees Of The University Of Illinois |
High affinity TCR proteins and methods
|
JP2002517223A
(ja)
|
1998-06-12 |
2002-06-18 |
ジェネンテック・インコーポレーテッド |
モノクローナル抗体、交叉反応性抗体およびそれを生成する方法
|
ES2327382T3
(es)
*
|
1999-07-20 |
2009-10-29 |
Morphosys Ag |
Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
|
AU784460B2
(en)
|
1999-08-23 |
2006-04-06 |
Chugai Seiyaku Kabushiki Kaisha |
HM1.24 antigen expression potentiators
|
AU5358901A
(en)
*
|
2000-04-17 |
2001-10-30 |
Dyax Corp |
Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
AU2002220275A1
(en)
*
|
2000-12-08 |
2002-06-18 |
The Board Of Trustees Of The University Of Illinois |
Mutated class ii major histocompatibility proteins
|
PT1360288E
(pt)
*
|
2000-12-18 |
2011-03-07 |
Dyax Corp |
Bibliotecas orientadas de pacotes genéticos
|
JP3986439B2
(ja)
|
2001-02-07 |
2007-10-03 |
中外製薬株式会社 |
造血器腫瘍の治療剤
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
EP1444344A4
(de)
*
|
2001-04-27 |
2005-08-24 |
Alexion Pharma Inc |
Neue phagenvektoren vom typ 88
|
US20040197911A1
(en)
*
|
2001-04-27 |
2004-10-07 |
Bowdish Katherine S. |
Novel 88 phage vectors
|
EP2075256A2
(de)
|
2002-01-14 |
2009-07-01 |
William Herman |
Gezielte Liganden
|
EP3578168A1
(de)
|
2002-02-14 |
2019-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Formulierung von antikörperhaltigen lösungen mit einem zucker als stabilisator
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
AU2003257536A1
(en)
|
2002-08-27 |
2004-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein solution preparation
|
CA2497364C
(en)
|
2002-09-11 |
2013-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Protein purification method
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
WO2005017155A1
(ja)
|
2003-06-18 |
2005-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーター
|
WO2005014818A1
(ja)
|
2003-08-08 |
2005-02-17 |
Perseus Proteomics Inc. |
癌高発現遺伝子
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
WO2006067847A1
(ja)
|
2004-12-22 |
2006-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
DK3050963T3
(da)
|
2005-03-31 |
2019-12-09 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
|
AU2006256041B2
(en)
|
2005-06-10 |
2012-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
RU2446826C2
(ru)
|
2005-10-14 |
2012-04-10 |
Фукуока Юниверсити |
Агенты для подавления повреждения трансплантированных островков после трансплантации островков
|
EP1941908B1
(de)
|
2005-10-21 |
2015-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutisches mittel gegen herzerkrankungen
|
WO2007055378A1
(ja)
|
2005-11-14 |
2007-05-18 |
Cell Signals Inc. |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
WO2007061029A1
(ja)
|
2005-11-25 |
2007-05-31 |
Keio University |
前立腺癌治療剤
|
JP5231810B2
(ja)
|
2005-12-28 |
2013-07-10 |
中外製薬株式会社 |
抗体含有安定化製剤
|
EP3135298B1
(de)
|
2006-01-27 |
2018-06-06 |
Keio University |
Therapeutische mittel für erkrankungen im zusammenhang mit choroidaler neovaskularisation
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
EP3345616A1
(de)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
|
EP2025346B1
(de)
|
2006-04-07 |
2016-08-10 |
Osaka University |
Mittel zur förderung der muskelregeneration
|
JP5242382B2
(ja)
|
2006-04-14 |
2013-07-24 |
株式会社医学生物学研究所 |
エフェクター機能を有するポリペプチド変異体
|
CL2007001665A1
(es)
|
2006-06-08 |
2008-01-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
|
JPWO2008007755A1
(ja)
|
2006-07-13 |
2009-12-10 |
中外製薬株式会社 |
細胞死誘導剤
|
EP2047862B9
(de)
|
2006-07-21 |
2013-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Mittel zur behandlung von nierenerkrankungen
|
CA2658050A1
(en)
|
2006-08-14 |
2008-02-21 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-desmoglein 3 antibodies
|
US20100297103A1
(en)
|
2006-09-14 |
2010-11-25 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
NZ576855A
(en)
|
2006-10-12 |
2012-08-31 |
Forerunner Pharma Res Co Ltd |
Diagnosis and treatment of cancer using anti-ereg antibody
|
AU2007311946A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
|
CA2666559A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
AU2007332473B2
(en)
|
2006-12-14 |
2012-09-27 |
Forerunner Pharma Research Co., Ltd. |
Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
|
EP2123676A4
(de)
|
2007-01-05 |
2011-01-05 |
Univ Tokyo |
Diagnose und behandlung von krebs unter verwendung von anti-prg-3-antikörpern
|
PE20081635A1
(es)
|
2007-01-23 |
2009-01-07 |
Chugai Pharmaceutical Co Ltd |
Agentes para suprimir la reaccion de rechazo cronica
|
WO2008105560A1
(ja)
|
2007-02-27 |
2008-09-04 |
Forerunner Pharma Research Co., Ltd. |
抗grp78抗体を有効成分として含む医薬組成物
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
EP2174667B1
(de)
|
2007-07-26 |
2017-01-04 |
Osaka University |
Mittel zur behandlung von augenentzündungen mit interleukin-6-rezeptorhemmer als wirkstoff
|
ES2403904T3
(es)
*
|
2007-08-21 |
2013-05-22 |
Morphosys Ag |
Métodos para la formación de enlaces disulfuro
|
RU2525133C2
(ru)
|
2007-08-30 |
2014-08-10 |
Дайити Санкио Компани, Лимитед |
Антитело к epha2
|
US8877688B2
(en)
*
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP3124497B1
(de)
*
|
2007-09-14 |
2020-04-15 |
Adimab, LLC |
Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
|
MX369784B
(es)
|
2007-09-26 |
2019-11-21 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
DK2196541T3
(da)
|
2007-09-28 |
2012-11-26 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican-3-antistof med forbedret kinetik i plasmaet
|
AU2008308163B2
(en)
|
2007-10-02 |
2013-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
|
WO2009048072A1
(ja)
|
2007-10-11 |
2009-04-16 |
Daiichi Sankyo Company, Limited |
破骨細胞関連蛋白質Siglec-15を標的とした抗体
|
CN103540632A
(zh)
|
2007-10-15 |
2014-01-29 |
中外制药株式会社 |
抗体的制备方法
|
EP2230300A4
(de)
|
2007-10-24 |
2012-08-08 |
Otsuka Chemical Holdings Co Ltd |
Polypeptid mit verbesserter effektorfunktion
|
JP5676107B2
(ja)
|
2007-11-14 |
2015-02-25 |
中外製薬株式会社 |
抗gpr49抗体を用いる癌の診断および治療
|
SG188134A1
(en)
|
2007-11-15 |
2013-03-28 |
Chugai Pharmaceutical Co Ltd |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
AU2008332271C1
(en)
|
2007-12-05 |
2014-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-NR10 antibody and use thereof
|
US8431127B2
(en)
|
2007-12-05 |
2013-04-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for treating pruritus comprising administering an NR10 antagonist
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
SG187457A1
(en)
|
2008-01-11 |
2013-02-28 |
Univ Tokyo |
Anti-cldn6 antibody
|
AU2009211253B2
(en)
*
|
2008-02-05 |
2014-11-06 |
Bicyclerd Limited |
Methods and compositions
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
NZ588029A
(en)
|
2008-03-14 |
2012-12-21 |
Allergan Inc |
Immuno-based botulinum toxin serotype a activity assays
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
CN107551270A
(zh)
|
2008-04-11 |
2018-01-09 |
中外制药株式会社 |
与多个分子的抗原反复结合的抗原结合分子
|
EP2281078B1
(de)
|
2008-04-24 |
2014-10-22 |
Dyax Corporation |
Bibliotheken von genetischen packungen, umfassend neue hc-cdr1, -cdr2, und -cdr3, und neue lc-cdr1-, -cdr2- und -cdr3-designs
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
TWI528973B
(zh)
|
2008-06-05 |
2016-04-11 |
Chugai Pharmaceutical Co Ltd |
Nerve infiltration inhibitor
|
CA2728473A1
(en)
|
2008-06-20 |
2009-12-23 |
National University Corporation Okayama University |
Antibody against oxidized ldl/.beta.2gpi complex and use of the same
|
WO2010017598A1
(en)
|
2008-08-14 |
2010-02-18 |
Arana Therapeutics Limited |
Anti-il-12/il-23 antibodies
|
US20120014870A1
(en)
|
2008-12-26 |
2012-01-19 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
UA104456C2
(uk)
|
2009-03-13 |
2014-02-10 |
Аллерган, Інк. |
Імунологічні тести на активність ендопептидаз із зміненою націленістю
|
EP2377932B1
(de)
|
2009-04-09 |
2020-11-18 |
Daiichi Sankyo Company, Limited |
Antikörper gegen siglec-15
|
EP2426149A4
(de)
|
2009-05-01 |
2013-01-23 |
Univ Tokyo |
Anti-cadherin-antikörper
|
EP2270053A1
(de)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanisierte AXL-Antikörper
|
CN102459591B
(zh)
|
2009-05-20 |
2015-05-13 |
诺维莫尼公司 |
合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
|
WO2010137654A1
(ja)
|
2009-05-29 |
2010-12-02 |
株式会社未来創薬研究所 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
SG10201404340TA
(en)
|
2009-07-31 |
2014-10-30 |
Shin Maeda |
Cancer metastasis inhibitor
|
CN102574917A
(zh)
|
2009-08-17 |
2012-07-11 |
株式会社未来创药研究所 |
含有抗hb-egf抗体作为有效成分的药物组合物
|
US20110082054A1
(en)
*
|
2009-09-14 |
2011-04-07 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
US8685524B2
(en)
|
2010-01-29 |
2014-04-01 |
Toray Industries, Inc. |
Polylactic acid-based resin sheet
|
KR101900110B1
(ko)
|
2010-02-10 |
2018-09-18 |
후지필름 알아이 파르마 가부시키가이샤 |
방사성 금속 표지 항카드헤린 항체
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
ES2932398T3
(es)
|
2010-05-28 |
2023-01-18 |
Chugai Pharmaceutical Co Ltd |
Potenciador de la respuesta de las células T antitumorales
|
US20130149302A1
(en)
|
2010-05-28 |
2013-06-13 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for pancreatic cancer
|
AU2011279073B2
(en)
|
2010-07-16 |
2016-06-09 |
Adimab, Llc |
Antibody libraries
|
PL2616090T3
(pl)
|
2010-09-17 |
2023-12-18 |
Takeda Pharmaceutical Company Limited |
Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
|
US9364505B2
(en)
|
2010-10-25 |
2016-06-14 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
WO2012057328A1
(ja)
|
2010-10-29 |
2012-05-03 |
株式会社ペルセウスプロテオミクス |
高い内在化能力を有する抗cdh3抗体
|
SG189456A1
(en)
|
2010-10-29 |
2013-05-31 |
Daiichi Sankyo Co Ltd |
Novel anti-dr5 antibody
|
JP6278598B2
(ja)
|
2010-11-30 |
2018-02-14 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
RU2658504C9
(ru)
|
2010-11-30 |
2018-08-21 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
|
KR20230005405A
(ko)
|
2011-02-25 |
2023-01-09 |
추가이 세이야쿠 가부시키가이샤 |
FcγRIIb 특이적 Fc 항체
|
AU2012233313C1
(en)
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
CN103826657A
(zh)
|
2011-04-04 |
2014-05-28 |
衣阿华大学研究基金会 |
改进疫苗免疫原性的方法
|
WO2012144208A1
(ja)
|
2011-04-18 |
2012-10-26 |
国立大学法人東京大学 |
抗itm2a抗体を用いる癌の診断および治療
|
KR102030987B1
(ko)
|
2011-04-25 |
2019-11-11 |
다이이찌 산쿄 가부시키가이샤 |
항 b7-h3항체
|
US9598496B2
(en)
|
2011-05-09 |
2017-03-21 |
Perseus Proteomics Inc. |
Antibody capable of specifically recognizing transferrin receptor
|
CN103827300A
(zh)
|
2011-06-30 |
2014-05-28 |
中外制药株式会社 |
异源二聚化多肽
|
US9366670B2
(en)
*
|
2011-07-04 |
2016-06-14 |
Samsung Electronics Co., Ltd. |
Polymer including group having at least two hydroxyls or zwitterionic group and use thereof
|
EP2735315B1
(de)
|
2011-07-19 |
2019-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Proteinhaltige stabile zubereitung mit argininamid oder valinamid
|
JP6101205B2
(ja)
|
2011-08-23 |
2017-03-22 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
WO2013035824A1
(ja)
|
2011-09-07 |
2013-03-14 |
ファーマロジカルズ・リサーチ プライベート リミテッド |
癌幹細胞の分離
|
MX366269B
(es)
|
2011-09-30 |
2019-07-04 |
Chugai Pharmaceutical Co Ltd |
Biblioteca de moleculas de union dependientes de la concentracion ionica.
|
EP2762493B1
(de)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
AU2012317418B2
(en)
|
2011-09-30 |
2017-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
CN104093424A
(zh)
|
2011-09-30 |
2014-10-08 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
EP3617313A1
(de)
|
2011-10-05 |
2020-03-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindendes molekül zur herstellung eines abstands zwischen einem plasma und einem antigen mit einer saccharidkettenrezeptor-bindenden domäne
|
EP2772268B8
(de)
|
2011-10-28 |
2020-01-08 |
Chugai Seiyaku Kabushiki Kaisha |
Krebsstammzellenspezifisches molekül
|
KR102168733B1
(ko)
|
2011-10-31 |
2020-10-23 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
RU2739792C1
(ru)
|
2011-11-30 |
2020-12-28 |
Чугаи Сейяку Кабусики Кайся |
Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
US9958437B2
(en)
|
2012-02-03 |
2018-05-01 |
The Governors Of The University Of Alberta |
Method of quantifying peptide-derivative libraries using phage display
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
US20160046693A1
(en)
|
2012-02-24 |
2016-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc gamma RIIB
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
CN104321430A
(zh)
|
2012-03-30 |
2015-01-28 |
第一三共株式会社 |
新颖的抗-siglec-15抗体
|
WO2013150623A1
(ja)
|
2012-04-04 |
2013-10-10 |
株式会社ペルセウスプロテオミクス |
抗cdh3(p-カドヘリン)抗体の薬剤コンジュゲート
|
SG10201608382QA
(en)
|
2012-04-09 |
2016-12-29 |
Daiichi Sankyo Co Ltd |
Anti-fgfr2 antibody
|
EP2841457B1
(de)
|
2012-04-27 |
2019-04-24 |
Daiichi Sankyo Company, Limited |
Anti-robo4-antikörper
|
DK2857419T3
(da)
|
2012-05-30 |
2021-03-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-bindende molekyle til eliminering af aggregerede antigener
|
TWI797443B
(zh)
|
2012-05-30 |
2023-04-01 |
日商中外製藥股份有限公司 |
抗原結合分子之篩選或製造方法
|
WO2013187495A1
(ja)
|
2012-06-14 |
2013-12-19 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
EP3597747B1
(de)
|
2012-08-24 |
2023-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Maus-fgcgammarii-spezifischer fc-antikörper
|
KR20210084688A
(ko)
|
2012-08-24 |
2021-07-07 |
추가이 세이야쿠 가부시키가이샤 |
FcγRIIb 특이적 Fc영역 개변체
|
KR101942148B1
(ko)
|
2012-09-27 |
2019-01-24 |
추가이 세이야쿠 가부시키가이샤 |
Fgfr3 융합 유전자 및 그것을 표적으로 하는 의약
|
SG11201502887WA
(en)
|
2012-10-11 |
2015-05-28 |
Daiichi Sankyo Co Ltd |
Antibody-drug conjugate
|
US9872924B2
(en)
|
2012-10-19 |
2018-01-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
HUE039920T2
(hu)
|
2012-11-08 |
2019-02-28 |
Univ Miyazaki |
Transzferrin receptor specifikusan felismerni képes antitest
|
ES2876009T3
(es)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Polipéptido heterodimerizado
|
WO2014163101A1
(ja)
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Fc領域改変体
|
EP2997378B1
(de)
|
2013-05-16 |
2018-08-08 |
Kyoto University |
Verfahren zur bestimmung der prognose von krebs
|
WO2014200018A1
(ja)
|
2013-06-11 |
2014-12-18 |
独立行政法人 国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
AU2014299916A1
(en)
|
2013-06-24 |
2015-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
|
WO2015034052A1
(ja)
|
2013-09-05 |
2015-03-12 |
国立大学法人 宮崎大学 |
ヒトインテグリンa6b4と特異的に反応する抗体
|
WO2015041310A1
(ja)
|
2013-09-20 |
2015-03-26 |
中外製薬株式会社 |
抗プロテインc抗体による出血性疾患の治療
|
US11124576B2
(en)
|
2013-09-27 |
2021-09-21 |
Chungai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
SG11201602490UA
(en)
|
2013-09-30 |
2016-04-28 |
Daiichi Sankyo Co Ltd |
Anti-lps o11 antibody
|
KR20160066024A
(ko)
|
2013-10-08 |
2016-06-09 |
다이이찌 산쿄 가부시키가이샤 |
항 fgfr2 항체와 타제의 조합
|
TWI712421B
(zh)
|
2013-11-11 |
2020-12-11 |
日商中外製藥股份有限公司 |
含改變的抗體可變區之抗原結合分子
|
MX2016007312A
(es)
|
2013-12-04 |
2017-01-13 |
Chugai Pharmaceutical Co Ltd |
Moleculas de union al antigeno, cuya actividad de union al antigeno varia de acuerdo con la concentracion de los compuestos y bibliotecas de dichas moleculas.
|
WO2015082724A1
(en)
|
2013-12-08 |
2015-06-11 |
Peptcell Limited |
Hiv antigens and antibodies and compositions, methods and uses thereof
|
NZ721213A
(en)
|
2013-12-25 |
2022-12-23 |
Daiichi Sankyo Co Ltd |
Anti-trop2 antibody-drug conjugate
|
RU2714967C2
(ru)
|
2013-12-27 |
2020-02-21 |
Чугаи Сейяку Кабусики Кайся |
Способ очистки антител с низкой изоэлектрической точкой
|
EP3581179A1
(de)
|
2013-12-27 |
2019-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
|
DK3101032T3
(en)
|
2014-01-31 |
2019-04-29 |
Daiichi Sankyo Co Ltd |
ANTI-HER2 ANTIBODY LÆGEMIDDELKONJUAGT
|
US10703798B2
(en)
|
2014-03-31 |
2020-07-07 |
Debiopharm International Sa |
Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)
|
MY195180A
(en)
|
2014-04-10 |
2023-01-11 |
U3 Pharma Gmbh |
Anti-HER3 Antibody-Drug Conjugate
|
EP4056993A1
(de)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur messung der viskosität einer proteinlösung
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
TWI805046B
(zh)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
EP3095465A1
(de)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
|
US11173213B2
(en)
|
2015-06-29 |
2021-11-16 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
DK3354729T3
(da)
|
2015-09-24 |
2024-04-22 |
Daiichi Sankyo Co Ltd |
Anti-garp-antistof
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
CA3016424A1
(en)
|
2016-03-14 |
2017-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
KR20190066026A
(ko)
|
2016-10-07 |
2019-06-12 |
다이이찌 산쿄 가부시키가이샤 |
항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료
|
EP3312290A1
(de)
|
2016-10-18 |
2018-04-25 |
Ipsen Biopharm Limited |
Zellulärer vamp-spaltungstest
|
MA46861A
(fr)
|
2016-11-16 |
2019-09-25 |
Janssen Biotech Inc |
Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
|
AU2017364818A1
(en)
|
2016-11-28 |
2019-05-23 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
AU2017379382A1
(en)
|
2016-12-22 |
2019-07-11 |
Daiichi Sankyo Company, Limited |
Anti-CD3 Antibody and Molecules Comprising the Antibody
|
US11434289B2
(en)
|
2017-01-17 |
2022-09-06 |
Daiichi Sankyo Company, Limited |
Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
|
MX2019008989A
(es)
|
2017-01-30 |
2019-10-09 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
|
JPWO2018147245A1
(ja)
|
2017-02-07 |
2019-11-21 |
第一三共株式会社 |
抗gprc5d抗体及び該抗体を含む分子
|
AU2018240938A1
(en)
|
2017-03-24 |
2019-10-10 |
Zenyaku Kogyo Co., Ltd. |
Anti-IgM/B cell surface antigen bispecific antibody
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
TW202330036A
(zh)
|
2017-05-15 |
2023-08-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
WO2019004487A1
(ja)
|
2017-06-30 |
2019-01-03 |
国立大学法人北海道大学 |
成長障害を生じない小児骨粗鬆症治療薬
|
CN111051513A
(zh)
|
2017-07-27 |
2020-04-21 |
第一三共株式会社 |
抗cd147抗体
|
EP3444275A1
(de)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoklonaler antikörper anti-fgfr4
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
SG11202001430SA
(en)
|
2017-09-29 |
2020-04-29 |
Daiichi Sankyo Co Ltd |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
JP7384668B2
(ja)
|
2017-10-05 |
2023-11-21 |
第一三共株式会社 |
細胞傷害性t細胞枯渇用組成物
|
JP7235249B2
(ja)
|
2017-10-20 |
2023-03-08 |
学校法人兵庫医科大学 |
抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
AU2018376309A1
(en)
|
2017-11-28 |
2020-06-25 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand-binding activity
|
EP3732195A4
(de)
|
2017-12-28 |
2022-02-09 |
Chugai Seiyaku Kabushiki Kaisha |
Zytotoxizitätsinduzierendes therapeutikum
|
JP7458790B2
(ja)
|
2018-01-31 |
2024-04-01 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
EP3762015A4
(de)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
|
SG11202008280TA
(en)
|
2018-03-05 |
2020-09-29 |
Univ Saitama Medical |
Pharmaceutical composition for treating or preventing heterotopic ossification
|
EP3797752A4
(de)
|
2018-05-21 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
In einem glasfläschchen verschlossene lyophilisierte formulierung
|
EP3824295A4
(de)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
Prädiktoren mit verzögerter wirkung nach behandlung mit anti-il23-spezifischem antikörper
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
CA3113837C
(en)
|
2018-09-24 |
2022-07-12 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
EP3882349A4
(de)
|
2018-11-14 |
2023-04-05 |
Daiichi Sankyo Company, Limited |
(anti-cdh6-antikörper)-(pyrrolobenzodiazepinderivat)-konjugat
|
MX2021005905A
(es)
|
2018-11-20 |
2021-06-23 |
Janssen Biotech Inc |
Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
|
EP3884959A4
(de)
|
2018-11-20 |
2022-08-10 |
Perseus Proteomics Inc. |
Inhibitor der zellulären eisenaufnahme
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
WO2020175689A1
(ja)
|
2019-02-28 |
2020-09-03 |
学校法人順天堂 |
切断型の変異型Calreticulinに結合する抗体、及び骨髄増殖性腫瘍の診断、予防又は治療薬
|
JP2022525145A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体組成物を生成するための製造方法
|
CN113853385A
(zh)
|
2019-03-18 |
2021-12-28 |
詹森生物科技公司 |
用抗il12/il23抗体治疗儿科受试者的银屑病的方法
|
JPWO2020189748A1
(de)
|
2019-03-19 |
2020-09-24 |
|
|
JPWO2020196475A1
(de)
|
2019-03-25 |
2020-10-01 |
|
|
KR20210143237A
(ko)
|
2019-03-25 |
2021-11-26 |
다이이찌 산쿄 가부시키가이샤 |
항체-피롤로벤조디아제핀 유도체 컨쥬게이트
|
US20220168438A1
(en)
|
2019-03-27 |
2022-06-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
|
WO2020209318A1
(ja)
|
2019-04-10 |
2020-10-15 |
中外製薬株式会社 |
Fc領域改変抗体の精製方法
|
CN114072173A
(zh)
|
2019-04-17 |
2022-02-18 |
国立大学法人广岛大学 |
以联合施用il-6抑制剂和ccr2抑制剂为特征的泌尿系统癌症治疗剂
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
CN113939318A
(zh)
|
2019-05-29 |
2022-01-14 |
第一三共株式会社 |
抗体-药物缀合物的制剂
|
WO2020246563A1
(ja)
|
2019-06-05 |
2020-12-10 |
中外製薬株式会社 |
抗体切断部位結合分子
|
JPWO2021020282A1
(de)
|
2019-07-26 |
2021-02-04 |
|
|
WO2021045184A1
(ja)
|
2019-09-04 |
2021-03-11 |
株式会社ペルセウスプロテオミクス |
多血症治療薬
|
JPWO2021079958A1
(de)
|
2019-10-25 |
2021-04-29 |
|
|
WO2021107082A1
(ja)
|
2019-11-27 |
2021-06-03 |
株式会社ペルセウスプロテオミクス |
癌性腹膜炎の治療薬
|
AU2020408213A1
(en)
|
2019-12-19 |
2022-06-23 |
Quidel Corporation |
Monoclonal antibody fusions
|
EP4129333A4
(de)
|
2020-03-27 |
2024-06-12 |
PhotoQ3 Inc. |
Pharmazeutisches arzneimittel zur zerstörung von tumorzellen
|
TW202204407A
(zh)
|
2020-03-30 |
2022-02-01 |
國立大學法人三重大學 |
雙特異性抗體
|
WO2021206078A1
(ja)
|
2020-04-06 |
2021-10-14 |
株式会社PhotoQ3 |
腫瘍細胞を死滅させるための医薬
|
WO2021261546A1
(ja)
|
2020-06-24 |
2021-12-30 |
国立大学法人 東京大学 |
光増感色素
|
KR20230047397A
(ko)
|
2020-07-28 |
2023-04-07 |
추가이 세이야쿠 가부시키가이샤 |
신규 개변형 항체를 포함하는, 바늘 실드를 구비한 바늘 부가 프리필드 시린지 제제
|
EP4197545A1
(de)
|
2020-07-31 |
2023-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmazeutische zusammensetzung mit einer zelle zur expression eines chimären rezeptors
|
EP4205764A1
(de)
|
2020-08-27 |
2023-07-05 |
Juntendo Educational Foundation |
Anti-trunkierter mutanter bispezifischer calr-cd3-antikörper und pharmazeutische zusammensetzung
|
EP4227686A1
(de)
|
2020-10-08 |
2023-08-16 |
National University Corporation Tokai National Higher Education and Research System |
Verfahren zur bestimmung der empfindlichkeit oder der medizinischen wirkung eines anti-transferrin-rezeptorantikörpers
|
KR20230146522A
(ko)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
항-dll3 항체-약물 접합체
|
JP2024503657A
(ja)
|
2021-01-13 |
2024-01-26 |
メモリアル スローン-ケタリング キャンサー センター |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
KR20230156368A
(ko)
|
2021-03-12 |
2023-11-14 |
추가이 세이야쿠 가부시키가이샤 |
중증 근무력증의 치료 또는 예방용의 의약 조성물
|
AU2022248779A1
(en)
|
2021-03-29 |
2023-09-28 |
Daiichi Sankyo Company, Limited |
Stable multispecific molecule and use thereof
|
JPWO2023027164A1
(de)
|
2021-08-26 |
2023-03-02 |
|
|
CA3231632A1
(en)
|
2021-09-15 |
2023-03-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
JPWO2023048231A1
(de)
|
2021-09-24 |
2023-03-30 |
|
|
WO2023057871A1
(en)
|
2021-10-04 |
2023-04-13 |
Novartis Ag |
Surfactant stabilizers
|
WO2023058723A1
(ja)
|
2021-10-08 |
2023-04-13 |
中外製薬株式会社 |
プレフィルドシリンジ製剤の調製方法
|
CN118119408A
(zh)
|
2021-10-18 |
2024-05-31 |
第一三共株式会社 |
抗cd37抗体-药物缀合物
|
EP4389895A1
(de)
|
2021-11-16 |
2024-06-26 |
National University Corporation Tottori University |
Künstlicher chromosomenvektor aus säugetieren mit einem schwerkettigen menschlichen immunoglobulin-locus mit modifizierter d-region und den vektor enthaltende zelle oder nichtmenschliches tier
|
TW202334238A
(zh)
|
2021-11-30 |
2023-09-01 |
日商第一三共股份有限公司 |
蛋白酶分解性遮蔽抗體
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|